BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 331 filers reported holding BIO-TECHNE CORP in Q1 2018. The put-call ratio across all filers is 0.86 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,613,465 | +37.4% | 67,775 | +64.7% | 0.01% | +60.0% |
| Q2 2023 | $3,358,267 | +116.4% | 41,140 | +426.2% | 0.01% | +25.0% |
| Q1 2019 | $1,552,000 | +40.8% | 7,818 | +2.7% | 0.00% | 0.0% |
| Q4 2018 | $1,102,000 | -42.2% | 7,613 | -18.4% | 0.00% | -20.0% |
| Q3 2018 | $1,905,000 | +32.3% | 9,332 | -4.1% | 0.01% | +25.0% |
| Q2 2018 | $1,440,000 | -2.3% | 9,734 | -0.2% | 0.00% | -20.0% |
| Q1 2018 | $1,474,000 | +100.8% | 9,754 | +72.2% | 0.01% | +150.0% |
| Q4 2017 | $734,000 | +10.9% | 5,665 | +3.4% | 0.00% | 0.0% |
| Q3 2017 | $662,000 | -0.6% | 5,479 | -3.4% | 0.00% | 0.0% |
| Q2 2017 | $666,000 | +17.0% | 5,671 | +1.2% | 0.00% | 0.0% |
| Q1 2017 | $569,000 | +16.4% | 5,603 | +17.8% | 0.00% | 0.0% |
| Q4 2016 | $489,000 | +74.6% | 4,758 | +86.3% | 0.00% | +100.0% |
| Q3 2016 | $280,000 | +4.1% | 2,554 | +7.1% | 0.00% | 0.0% |
| Q2 2016 | $269,000 | -16.7% | 2,384 | -26.0% | 0.00% | 0.0% |
| Q1 2015 | $323,000 | -41.4% | 3,220 | -46.0% | 0.00% | -50.0% |
| Q4 2014 | $551,000 | – | 5,968 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $13,206,000 | 5.33% |
| Montanaro Asset Management Ltd | 101,950 | $28,954,000 | 4.43% |
| Jackson Square Partners, LLC | 521,991 | $148,245,000 | 3.89% |
| Sandhill Capital Partners LLC | 119,671 | $33,987,000 | 3.88% |
| STONE RUN CAPITAL, LLC | 22,055 | $6,264,000 | 3.38% |
| Ownership Capital B.V. | 610,466 | $173,372,000 | 3.35% |
| Brown Capital Management | 823,303 | $233,818,000 | 3.28% |
| DF DENT & CO INC | 671,348 | $190,663,000 | 2.94% |
| Westwind Capital | 27,931 | $7,932,000 | 2.78% |
| MAIRS & POWER INC | 673,620 | $191,308,000 | 2.41% |